Salute e Benessere

Kaneka Files Patent Infringement Lawsuit Against CoCrystal

Kaneka is also committed to enforcing its patent rights against any customer who purchases the Accused Product from CoCrystal and subsequently engages in activities such as using, selling, or offering to sell the Accused Product within the United States. This may involve taking legal action against these customers, which could include adding them as additional defendants in the lawsuit against CoCrystal or initiating separate legal proceedings to address their patent infringement. Kaneka is...
PR Newswire
09/10/2023

Pixium Vision announces the opening of safeguard proceedings

Pixium Vision announces the opening of safeguard proceedings Paris, France, October 9, 2023 – 19:00 (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX) (the “ Company ”), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces the opening today of safeguard proceedings by the Commercial Court of Paris.Indeed, despite all the efforts made in the research of...
Nasdaq GlobeNewswire
09/10/2023

Intraoperative Neuromonitoring Market Size to Grow at a CAGR of 5.9% | Valuates…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-13V12306/Global_Intraoperative_Neuromonitoring_IONM Get Free Sample:https://reports.valuates.com/request/sample/QYRE-Auto-13V12306/Global_Intraoperative_Neuromonitoring_IONM Major Factors Driving the Growth of Intraoperative Neuromonitoring Market : The market for intraoperative neurophysiological monitoring will be driven by the rising number of patients who have been diagnosed with various disorders in recent...
PR Newswire
09/10/2023

Hansa Biopharma announces encouraging high-level results for first-in-human…

NICE-01 is a double blind, randomized, placebo-controlled trial evaluating safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of HNSA-5487 administered as a single intravenous (IV) infusion. The trial included a total of 36 healthy male and female adult participants. NICE-01 is a double blind, randomized, placebo-controlled trial evaluating safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of HNSA-5487...
PR Newswire
09/10/2023

Clinical Trial Supplies Market worth $6.3 billion | MarketsandMarkets

The growth of the market is projected to be driven by factors such as collaborations & partnerships among market players for clinical trial outsourcing service, increasing R&D expenditure by biopharmaceutical and pharmaceutical companies and the growing the number of clinical trials conducted across the globe. The growth of the market is projected to be driven by factors such as collaborations & partnerships among market players for clinical trial outsourcing service, increasing…
PR Newswire
09/10/2023

Urology Devices Market size worth USD 58.46 Billion, Globally, by 2030 at 6.7%…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=31560 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=31560 Browse in-depth TOCon" Urology Devices Market " 202 - Pages 126 – Tables 37 – Figures Global Urology Devices Market Report Unveils Key Insights: Technological Innovations and Rising Renal Disorders Drive Market Growth In a comprehensive market research report released today, experts have...
PR Newswire
09/10/2023

Home Appliances Market Size to Grow USD 282150 Million by 2029 at a CAGR of 4.4%…

Major Factors driving the growth of Home Appliances Market Major Factors driving the growth of Home Appliances Market Home appliances market growth is influenced by a number of variables, including rising consumer expenditure, including per capita income, and changing customer preferences. During the pandemic, the work-from-home movement gained popularity, which helped to fuel an increase in demand for white goods on a global scale. People spent more time at home in 2020, which prompted...
PR Newswire
09/10/2023

Empowering Arthritis Disease Players with Disease Insights, Epidemiology Study…

Disease Landscape Insights healthcare consulting services are being procured by the industry players at a large scale. DLI plays a vital role in the management of arthritis by offering a comprehensive range of services and expertise. Its services encompasses clinical trial assessment, epidemiology study, and disease burden analysis, which provide valuable insights into the nature and impact of arthritis. Furthermore, it assists in drug development and drug launch strategies, ensuring that…
PR Newswire
09/10/2023

Drug Delivery Technology Market is expected to reach US$ 143.5 billion by 2033 |…

Download the Sample PDF Summary for an overview of the Comprehensive Research Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1166 Download the Sample PDF Summary for an overview of the Comprehensive Research Report:https://www.futuremarketinsights.com/reports/sample/rep-gb-1166 How are Manufacturers Bringing New Opportunities in the Global Market? Manufacturers bring new technology, trends, and innovations that drive new opportunities in the global...
PR Newswire
09/10/2023

Bipolar Disorder Landscape Report with DLI's Clinical Trial Assessment, Product…

Healthcare consulting services provided by DiseaseLandscape Insights are being obtained by the industry participants from across the globe. From treatment gaps identification, drug development, clinical trial feasibility analysis, and product pipeline assessment to price and market access, regulatory consulting, and commercial strategy analysis plans, DLI has been empowering them with the much-needed assistance. They are also leveraging DLI's market intelligence repository that can aid in the…
PR Newswire
09/10/2023

Endotronix Receives IDE Approval for the Market Expanding PROACTIVE-HF 2…

The PROACTIVE-HF 2 prospective, open-label randomized controlled clinical trial will enroll up to 1,500 patients in the U.S. and Europe. The dual arm study design was presented over the weekend at HFSA and the first patient is expected to be enrolled later this year. The randomized arm will assess the safety and efficacy of PA pressure-guided therapy using Cordella in NYHA class II patients at risk for congestion. In both cohorts, patients and clinicians will have access to daily trended…
PR Newswire
09/10/2023

Kexing Biopharm Holds China-MENA & South Asia Pharmaceutical Cooperation…

Kexing Biopharm has been deeply engaged in overseas markets for many years, with a presence in more than 40 countries worldwide. Since its IPO, the company has prioritized overseas business expansion as one of its three major strategies. MENA and South Asia are among the earliest overseas markets where the company established its presence. In 2022, the company established its subsidiary in Egypt and officially initiated local operations. Since then, it has been accelerating its expansion and…
PR Newswire
09/10/2023

Virbac will enter the fast-growing poultry vaccines segment in India

Virbac announces the signing of an agreement to acquire Globion, a leading Indian poultry vaccines specialist. This transaction will bolster our position of animal health market leader in India by extending Virbac India's existing poultry portfolio to the growing segment of avian vaccines.Founded in 2005, as a joint venture between Suguna Group, one of the leading Indian poultry conglomerates, and Lohmann Animal Health, a German poultry vaccines specialist, Globion has developed robust...
Nasdaq GlobeNewswire
09/10/2023

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 09 October 2023– On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under…
Nasdaq GlobeNewswire
09/10/2023

Skylight to Present New Study Correlating Spiritual Practices to Lower Anxiety

"Today's conversation regarding mental health is incomplete without discussing spiritual wellness as a contributor to overall human wellness," said John Dye, executive director at Skylight. "The link between spiritual practice and mental wellness for Gen Z and young Millennials is just now beginning to be understood, and we are grateful that they are benefiting from our service. We are committed to providing data-backed tools and practices to help our users find the peace that…
PR Newswire
09/10/2023

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application…

OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP.Second clinical indication for OK-101 which is currently in 240-patient Phase 2 clinical trial to treat dry eye disease, with top-line data anticipated in December 2023. LONDON and NEW YORK, Oct.09, 2023(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical stage...
Nasdaq GlobeNewswire
09/10/2023

AMBU ANNOUNCES PRELIMINARY FINANCIAL RESULTS FOR THE FISCAL YEAR 2022/23

/23 results. For the financial year 2022/23, EBIT before special items totalled DKK 302m, with an EBIT margin before special items of 6.3% (previous outlook: 5 – 6%), mainly driven by scale in OPEX and product mix.PRELIMINARY FINANCIAL HIGHLIGHTS FOR THE FULL FINANCIAL YEAR 2022/23Last year's comparative figures are stated in brackets. Revenue was DKK 4,775m (DKK 4,444m), with organic growth of 7.6% (4%), driven by strong growth in Endoscopy Solutions. Reported growth for the year...
Nasdaq GlobeNewswire
09/10/2023

Transforming Bronchitis Disease Management with DLI's Drug Insights, Price and…

Price and Market Access Price and Market Access Medical researchers, pharmaceuticals, and other related healthcare bodies are involved in continuous R&D activities with an aim to transform the diagnostic and treatment dynamics of this disease. In this journey, many of them seek healthcare consulting services from DLI to get complete disease overview, market intelligence, along with drug development and clinical trial management-based assistance. It also helps them with clinical trial...
PR Newswire
09/10/2023

Redefining Colorectal Cancer (CRC) Landscape Report with DLI's Epidemiology…

Price and Market Access Price and Market Access The Market Competitors Listed Below are Revolutionizing Healthcare with Innovative Diagnostic Inventions: Learn More About the FDA NDA & BLA Approval (NME) Drugs for Colorectal Cancer @ https://www.diseaselandscape.com/requestsample/postid/90 DiseaseLandscape Insights has been offering healthcare consulting services to the players operating in this vertical. It is assisting them with clinical trial feasibility analysis,...
PR Newswire
09/10/2023

Reshaping Cystic Fibrosis Disease Landscape Report | Epidemiology Study, Drug…

DiseaseLandscape Insights has been providing the players with disease insights, allowing them to understand the characteristics, traits, and cystic fibrosis symptoms comprehensively. They are leveraging DLI's healthcare consulting services to accelerated their cystic fibrosis research & development activities. This health consultant is also helping them with clinical trial management, market entry strategy, product portfolio extension, treatment gaps identification, along with pricing and…
PR Newswire
09/10/2023

Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase…

The Phase 2a multicentric, randomized, placebo-controlled, split-body trial will evaluate the efficacy of ACOU085 for preventing cisplatin-induced ototoxicity in young male patients diagnosed with testicular cancer. The clinical study will assess several efficacy outcomes for ACOU085, including changes in high-frequency, pure-tone audiometry, speech comprehension in quiet and noisy environments, and otoacoustic emissions. The enrolment of the first patients is expected in late 2023. The Phase...
PR Newswire
09/10/2023

Reshaping Graves Disease Landscape with DLI's Clinical Trial Management…

Numerous medical researchers, pharma companies, and other healthcare organizations are trying to enter into the rare disease management vertical. They are conducting research & development activities to get a deep understanding of such ailments and develop diagnostic and treatment solutions for the same. DiseaseLandscape Insights has been offering healthcare consulting services to such players. It has been helping them with drug development, treatment gaps identification, product portfolio…
PR Newswire
09/10/2023

Transforming Lymphoma Management Landscape with DLI's Disease Insights, Unmet…

DiseaseLandscape Insights (DLI) play a pivotal role in assisting lymphoma stakeholders across various aspects of the disease, from drug development to market access. DLI offer a comprehensive understanding of lymphoma's epidemiology and subtypes, aiding drug developers in identifying potential therapeutic targets and tailoring treatments. They also facilitate clinical trial management by providing valuable patient data and helping to design more effective trials. Moreover, DLI assists in…
PR Newswire
09/10/2023

Syphilis Disease Management- Role of DLI in Clinical Trial Management…

Price and Market Access Price and Market Access Disease Landscape Insights has been a forefront when it comes to accumulating a comprehensive disease overview. Its deep dive expertise in providing healthcare consulting services is helping players navigating through clinical trial feasibility analysis, commercial strategy analysis, treatment gaps identification, along with price and market access, among others. It has also been assisting them with new product development services, drug...
PR Newswire
09/10/2023
Altri  Comunicati